Biotec Pharmacon. Capital Markets Day. 11. February 2016

Transcription

1 Biotec Pharmacon Capital Markets Day 11. February 2016

2 Agenda Time Presentation Presenter Introduction Setting the scene CEO Svein Lien Innate immunity and Biotec s beta-glucans Woulgan product development Woulgan - wound care: Vision, positioning and market opportunity Market updates and commercial activities Product potential and outlook CSO Rolf Engstad VP Marketing Stuart Devine Immunotherapy of Cancer CSO Rolf Engstad Q&A All ArcticZymes value proposition MD Jethro Holter Q&A All Closing remarks and outlook CEO Svein Lien 2

3 Biotec in brief A corporation of two independent versatile technology platforms Beta-Glucans: Proprietary Beta-Glucans Immuno-modulatory substance activating the immune system Building up international sales organization in wound care Bulk sales of products for Animal Health and Nutrition Strong and experienced scientific team with in-house production Enzymes - ArcticZymes: Unique Cold-adapted Enzymes for the life science industry based on species from the Barents Sea International marketing and sales team Established relation with core industrial companies (B2B) Strong and experienced scientific team with in house production 3

4 Biotec in brief A corporation of two independent versatile technology platforms Value proposition Beta-Glucans: To become a competitive supplier of advanced wound care products under the Woulgan brand while continue to build the other business areas including cancer Value proposition Enzymes: To expand the business into key platform technologies with a ground breaking strategic value Biotec is emerging into a commercially driven company Biotec Pharmacon ASA 4

5 Objectives with the Capital Market Day: Up to 2015 both business units have been establishing their respective strategic platforms During 2015 both took major steps towards fulfilling the value propositions: ArcticZymes reached break-even results with good growth, strengthen its management and used the established co-operation with industry s market leaders to initiate development of new products with a substantial strategic value Beta-Glucans started the build up of a wound care company with at least a $100M potential, employing a number of experienced commercial key people, appointed distributors and started pre-launch activities The objectives with the CMD is to describe to you what Biotec has accomplished and where the Company is going Biotec Pharmacon ASA 5

6 Agenda Time Presentation Presenter Introduction Setting the scene CEO Svein Lien Innate immunity and Biotec s beta-glucans Woulgan product development Woulgan - wound care: Vision, positioning and market opportunity Market updates and commercial activities Product potential and outlook CSO Rolf Engstad VP Marketing Stuart Devine Immunotherapy of Cancer CSO Rolf Engstad Q&A All ArcticZymes value proposition MD Jethro Holter Q&A All Closing remarks and outlook CEO Svein Lien 28

7 Innate immunity how is it triggered? Innate immunity Adaptive immunity Main function How are pathogens recognised Prevent microorganisms (bacterial, fungal and viral pathogens) to invade the host & eliminate «non-self» By fixed structures on pathogen groups Learn to recognise any structure on pathogens Response time Immediate Need days/weeks Cells involved Neutrophils, NK-cells Macrophages T- and B-cells (antibodies) Macrophages are known as Metchnikoffs soldiers killing pathogens & instructing the immune system Beta-glucans are recognised by macrophages as «representatives» for a fungal attack Metchnikoff Elia (1887). "Sur la lutte des cellules de l organisme contre l invasion des microbes- On fighting cells of the body against invading microbes. Ann. Inst. Pasteur 1: 32 «Training of macrophages by beta-glucan» Saeed et al. Science

8 Beta-Glucan product portfolio M-Glucan Feed ingredient NBG Particulate Nutrition Animal Health: Deliver feed ingredients to improve animal health in e.g. fish farming Nutrition: Deliver bulk ingredients for food supplements NBG Cos Cosmetics Cosmetic: Deliver bulk ingredients for cosmetic products SBG Soluble Beta-Glucan (Medicinal product) Medicinal: Produces SBG for use in medical devices and for clinical trials as adjuvant in cancer treatment Biotec Pharmacon ASA 8

9 Anti-virus signal molecule M-Glucan in aquaculture Anti-viral response to M-Glucan in fish feed Standard feed M-Glucan feed 0 Negative ctr "Virus infection" Trigger of response in Atlantic salmon Biotec Pharmacon ASA 9

10 Biotec s SBG triggers innate immune responses Biotec SBG is tailored for optimal binding to cells of the innate immune system, especially the macrophages triggering controlled and well regulated production of: Signal molecules alerting the immune system Growth factors supporting cell growth Increased bacterial killing and phagocytosis Increased antigen presentation Ideal candidate for many immunotherapeutic applications SBG is patent protected by a number of patent families covering production, formulation and application Biotec Pharmacon ASA 10

11 Proliferating cell count (fov) % Contraction SBG in wound care the results of macrophage activation SBG activates macrophages to produce signal molecules and growth factors resulting in: Increased wound contraction (bringing the wound edges closer to each other) Increased cell proliferation (new cells to support the healing process) New formation of blood vessels (angiogenesis) Increased healing Wound contraction Water Woulgan Biogel «Woulgan Biogel» without SBG Angiogensis Count (fov) (ref.: Skjæveland & Engstad 2013) 0 0 Marginal Intermediate Centre Marginal Intermediate Centre Cell proliferation Angiogenesis Biotec Pharmacon ASA 11

12 Product development Woulgan A technology platform in Wound care Next generation products: Woulgan compositions have been formulated as a dry dressing and spray The dressing composition is aimed for use on large exuding wounds where the gel format is less suitable The spray formulation is aimed for use on larger surface wounds like burns The products were tested in slow healing mice model (db/db mice). Ten mice used in each treatment group 12

13 % Wound Area Remaining Woulgan in Spray - Proof of concept obtained Water Spray ctr (no SBG) "Woulgan" Spray Woulgan Gel Days Post-wounding Woulgan Spray in healing of wounds in db/db mice. Spray applied at Day 0, 2, 4 and 6. Spray control without SBG (water, CMC, glycerol) Woulgan spray with SBG Woulgan gel Water water control with occlusive dressing only. Biotec Pharmacon ASA 13

14 % Wound Area Remaining Woulgan in Dressings - Proof of concept obtained Water Dressing ctr (no SBG) "Woulgan" dressing Dry Woulgan Dressing in healing of wounds in db/db mice. Dressing applied at Day 0, 3, 6 and 9. Dressing control without SBG Woulgan dressing with SBG; Water water control with occlusive dressing only Days Post-wounding Biotec Pharmacon ASA 14

15 Woulgan development program Product Discovery/ formulation Pre-clinical proof of concept Clinical evaluation (medical device) Approval Market access Launch growth Woulgan Gel Current Woulgan Spray Current 2016/ /2018 Woulgan «Hydrofiber» Dressing Woulgan «Combination» Dressing Current Current / /2020 Biotec Pharmacon ASA 15

16 Agenda Time Presentation Presenter Introduction Setting the scene CEO Svein Lien Innate immunity and Biotec s beta-glucans Woulgan product development Woulgan - wound care: Vision, positioning and market opportunity Market updates and commercial activities Product potential and outlook CSO Rolf Engstad VP Marketing Stuart Devine Immunotherapy of Cancer CSO Rolf Engstad Q&A All ArcticZymes value proposition MD Jethro Holter Q&A All Closing remarks and outlook CEO Svein Lien 2

17 Vision: Building a >USD100M Wound Care Company Bioactive Beta-Glucan technology demonstrated ability to kick-start stalled wounds where healing slowed or stopped: Clinical Practice -Key Opinion Leader Support Market Access -Product is available & affordable Woulgan becomes the lead option to reactivate wound healing >$100m opportunity Go-to-Market -Commercial organisation Positioning for stalled wounds allows Woulgan to show: more healing benefit versus standard of care stronger, positive clinician experiences BURNS DFU WOULGAN Platform PU VLU Clear, clean and credible message on when to use and when to not use Woulgan across multiple wound types 17

18 Stalled Chronic Wounds/(000 s) Stalled Wounds: A Growing, Global Issue US: DFU costs $9-13 billion per annum* US: diabetic population to double to 44 million by 2034 US: VLU incidence at 2.2% of population, costing $14.9 billion** China: diabetes prevalence at 11.6% of population A Substantial Burden: UK Example UK NHS managed 600K chronic wounds 3.0 billion annual cost of treating unhealed wounds (all types) Time to heal is main driver of cost in wound care Globally >5M stalled wounds ( >60% of all chronic wounds): Stalled Wounds by Market VLU DFU 200 PU G2/3-35 Million Visits to Care for Chronic Wounds in UK Practice nurse Community nurse G.P. Hospital Outpatient *Rice JB1, Diabetes Care. 2014;37(3): **Rice JB1, J Med Econ May;17(5): Prof. Biotec Xiaobing Pharmacon Fu ASA EWMA Journal 2015 vol 15 no 1 BMJ Open 2015;5, issue BBG analysis:not responding after 4 weeks treatments with standard of care

19 Percentage of Patients/(%) SBG Standard of Care Ave. Patient Cost/( ) Woulgan Improves Outcomes AND Reduces Costs 2.3 times more patients healed at 8 weeks* (44% vs. 17% in control) Woulgan heals faster, saving 44% costs** % Patients with Complete Healing 56% Cost to Reach Standard Healing rates (12 weeks) -44% % 37% , Standard of Care WOULGAN 0 Duration of Therapy/(Weeks) *Zykova et al **UK Drug Tariff submission based on Zykova et al 19

20 Woulgan Value Proposition $ Patients Clinicians Payers Comfortable, effective therapy proven to accelerate healing Delivering improved quality of care, proven to give faster results Familiar format, easy to apply & well tolerated by patients Demonstrated value release from broad adoption of an effective therapy & the associated improved outcomes Biotec Pharmacon ASA 20

21 Simplicity and Convenience add to Competitive Advantage Existing Standard of Care is our target; there are no dominant competitive active therapies in advanced wound care WOULGAN is a powerful accelerator of healing, delivered in a gel format which is already routinely used by healthcare practitioners; making it simple to include in their existing treatment plans Reactivate the healing process with a small step in clinical practice 21

22 Woulgan Holds a High Potential Value A higher potential value based on the stronger evidence supporting class III registration: Go-to-Market Market Access Clinical Practice Medical device distributors build Woulgan Brand highly capable sales organisation excellent reputation, customer network & focused on Woulgan brand Register product to differentiate from future competition Win good pricing (evidence, claims & economic benefit) via reimbursement or tenders Build Woulgan support with Key Opinion Leaders (KOLs) Accelerate generalist adoption via KOL recommendations Benefit of Market Preparation Years Post Launch Without Market Preparation Market Preparation Launching in Key Markets: UK Scandinavia Germany 22

23 UK wound care market Market size 195K stalled wounds* across acute and community 65m stalled wound opportunity Market Access (reimbursment/tenders) In community Woulgan is prescribed and reimbursed National Pricing Mechanism is Drug Tariff In hospital availability via NHS Supply Chain allows convenient supply Clinical Practice 232 local formularies (guidelines for prescribing) guides generalist use Biotec Pharmacon ASA *BBG analysis 23

24 UK launch update: H1 activities Go-to-Market X2 sales heads pre-launch X5 congresses Q2 webcast YouTube videos Q3 Full launch (12 heads) Market Access Mid-Year Drug Tariff approval Clinical Practice X40 clinicians trained X20 active evaluation sites >100 patients treated with Woulgan (DFU/VLU/PU) March Woulgan.com goes live June evaluation reviews 24

25 Nordic wound care market Market size 77K stalled wounds*; acute and primary care 28m stalled wound opportunity Market Access (reimbursment/tenders) No reimbursement but several counties tender for medical devices HCP may buy outside tenders but not preferred (low volumes) Sometimes home care patients pay out-of-pocket (low volumes) Clinical Practice KOLs and influencers based in hospitals (only see 20% of wounds) 80% management of stalled wounds in primary care Biotec Pharmacon ASA *BBG analysis 25

26 Nordic launch update: H1 activities Go-to-Market 4 KAMs trained January Q1 sample campaign X8 congresses Q2 full launch with 14 heads Market Access Building tenders calendar Engaging tender co-ordinators Mapping patient flow Clinical Practice Identifying & visiting KOLs X20 commercial evaluation sites >100 patients treated with Woulgan Q1-2 meetings with all wound centres 26

27 German wound care market and update Market size: Ongoing processes Germany: 240K stalled wounds*; acute and primary care 86m stalled wound opportunity Market Access (reimbursment/tenders) In community dressings are prescribed and reimbursed National decision on outpatient reimbursement by G-BA 132 Sick Funds reimburse agreed outpatient treatments Go-to- Market Market Access Shortlisting partners Regional & national Agree distribution Expert engaged, strategy in development Clinical Practice In contact with facilities for testing and KOL support Biotec Pharmacon ASA *BBG analysis 27

28 How to achieve strong US Reimbursement Beginning with 510K application (predicated on MacroPro gel by Mölnlycke) Recommended first step in registration Define market access strategy: US clinical trial? 2016 Milestones: 510K application to be sent Q1 510K approval: expected end Start partner process autumn Registration Reimbursement After effective reimbursement is available then execute launch Biotec Pharmacon ASA 28

29 Outlook: the next three years By end 2016 UK reimbursement approved Growing sales UK and Scandinavia Building and development of sales support organisation Distribution agreement and pre-launch activities in Germany By end 2018 Established market position in UK and Scandinavia and good traction in Germany Distribution in selected European countries US process at advanced stage Canada follows US China and Japan in progress Biotec Pharmacon ASA 29

30 Woulgan has a potential of at least USD 100M By 2020 Woulgan brand offers multiple solutions for different types of stalled wound By 2025 we foresee Woulgan share between 8-13% of stalled wounds in key global markets Full Commercialisation in Key European markets Launch of Spray & Combination Products Full Commercialisation in U.S. Execute >USD 100m Early Penetration in Asia Biotec Pharmacon ASA 30

31 Agenda Time Presentation Presenter Introduction Setting the scene CEO Svein Lien Innate immunity and Biotec s beta-glucans Woulgan product development Woulgan - wound care: Vision, positioning and market opportunity Market updates and commercial activities Product potential and outlook CSO Rolf Engstad VP Marketing Stuart Devine Immunotherapy of Cancer CSO Rolf Engstad Q&A All ArcticZymes value proposition MD Jethro Holter Q&A All Closing remarks and outlook CEO Svein Lien 2

32 SBG in immunotherapy of cancer Phase I studies (safety) performed in four different cancer studies: Non-Hodgkins lymphoma combining SBG with mab Rituximab Breast cancer combining SBG with mab Herceptin Neuroblastoma combining SBG with Memorial Sloan Ketterings proprietary mab 3F8 Neuroblastoma combining SBG with Memorial Sloan Ketterings proprietary vaccine against ganglioside D2 and D3 (Kushner et al 2014, Clinical Cancer Research 20: ). Biotec Pharmacon ASA 32

33 SBG in immunotherapy of cancer Investigator driven single arm vaccine trial in children with neuroblastoma initiated by MSKCC using their own developed bivalent vaccine against neuroblastoma antigens (GD2L and GD3L). Biotec s SBG given p.o. to increase tumor killing activity of white blood cells Phase I part (safety) of studie (15 patients) finalised in 2013 Combination was safe and positive responses observed Phase II part (efficacy) of study ongoing aiming to recruite 100 patients (115 in total) Currently 53 patients treated Expeceted to recruite about 20 patients per year Kushner et al 2014, Clinical Cancer Research 20: Biotec Pharmacon ASA 33

34 IPR - SBG in immunotherapy of cancer Patents filed in: USA, Europe, Canada, Australia, China, Japan, India, South-Korea, Brazil and Mexico Presently overall 16 patents granted; 6 patent applications pending Patent and application claim scope: Composition of matter (beta-glucans/monoclonal antibodies) Method of treatment of cancer by applying the above concepts Use of concepts in cancer therapy 34

35 Outlook immunotherapy of cancer The results the ongoing study at Memorial Sloan Kettering Cancer Center (MSKKC) will be important references of SBG as an adjuvant for cancer therapies The Company will consider the possibilities of doing similar studies as performed by MSKCC at other hospitals running investigator driven trials within immunotherapy of cancer both in combination with cancer vaccines and with mab therapy but are not prepared to pay for such studies The company will consider partnerships to pursue this opportunity to retain its main focus in the wound care area The patent portfolio covers a broad range of combination therapies, and the company is open for possible out-licensing opportunities Biotec Pharmacon ASA 35

36 Agenda Time Presentation Presenter Introduction Setting the scene CEO Svein Lien Innate immunity and Biotec s beta-glucans Woulgan product development Woulgan - wound care: Vision, positioning and market opportunity Market updates and commercial activities Product potential and outlook CSO Rolf Engstad VP Marketing Stuart Devine Immunotherapy of Cancer CSO Rolf Engstad Q&A All ArcticZymes value proposition MD Jethro Holter Q&A All Closing remarks and outlook CEO Svein Lien 2

37 ArcticZymes AS Oslo, 11 th February 2016 Jethro Holter Managing Director

38 Agenda What is an enzyme & their utility Target markets ArcticZymes unique value proposition Arctic Access: Leveraging uniqueness Commercial Capabilities: Products & pipeline B2B Approach: Commercial partnering Outlook for ArcticZymes Biotec Pharmacon ASA 38

39 What is a Molecular Enzyme? Enzyme a protein that performs a specific job = "Engine" Molecular Enzymes do jobs associated with DNA or other genetic material Proteinases Digest cells to release DNA dsdnase Selectively cuts up double stranded DNA Ligase Joins DNA together Polymerase Amplifies/Copies DNA ArcticZymes core business is centred around novel molecular enzymes Biotec Pharmacon ASA 39

40 ArcticZymes Enzymes are Utilised in Molecular Workflows Simplified Workflow: Proteinase Polymerase Cod UNG, rsap, Ligases, etc.. Sanger Sequencing Next Generation Sequencing (NGS) Cells DNA Amplified DNA Workflows form the basis of activities in Molecular Research and Molecular Diagnostics Detection and Analysis Real time PCR Many commercial players offer either partial or complete workflows e.g. Thermo, Roche, Siemens, Abbott, Alere ArcticZymes core business is about supporting its commercial partners to market in developing leading edge workflows through its novel enzymes Biotec Pharmacon ASA 40

41 Cost per Gemone The Human Genome - Sequencing $95M Next Generation Sequencing Our future polymerases as well as our other enzymes feature in NGS $10M Sanger Sequencing 1 st Gen Sequencing ABI st Human Genome Sequenced 2 nd Gen Sequencing $1K $100 Sanger Sequencing ArcticZymes rsap is abundantly used today Roche 454 Life Tech Benchtop Sequencing Ion Torrent Illumina 3 rd Gen Sequencing Pac Bio Sequencing Market 2016 Estimated $2,4 Bil (16% CAGR) Biotec Pharmacon ASA 41

42 Molecular Diagnostics (MDx) Molecular Research Large platforms Points Of Care Specialised/Lab Developed Test Qiagen kit Isolate DNA Thermo kit Amplification (PCR) Affymetrix kit Clean up DNA or genetic tests used to diagnose, and prevent disease as well as guides treatment: Infectious Disease (HIV, HCV, Influenza) Cancer (colorectal, prostate) Prenatal care (Down Syndrome, Turners, Edwards) Dominated by instrument platforms running integrated workflows Highly regulated FDA/EU regulatory authorities Enzymes are very essential components. Unique features are often demanded Market Size: $6,5 Bil (8,5% CAGR) in 2016 Advancing our understanding and knowledge about DNA and other genetic material Kits are used in sequential fashion in performing workflows Large diversity of kits on the market which can be combined to achieve the desired workflow Majority of kits are driven by enzymes. Leading technologies demand novel enzymes Market size: $8,9 Bil (6% CAGR) in 2016 Molecular Enzymes - $1,5 Bil today (8,3% CAGR) Biotec Pharmacon ASA 42

43 ArcticZymes Unique Value Proposition Arctic Access Direct access to unique bioprospecting libraries via University of Tromsø Commercial Capability Internal capabilities to translate into high value & novel enzyme products B2B Approach Commercial Partnering - collaborate and provide our solutions to global players in Molecular Research & Diagnostics Biotec Pharmacon ASA 43

44 Commercialising the Arctic s Uniqueness Leveraging Uniqueness Arctic Bioprospecting Driven by University of Tromsø (UiT) Large biobank of novel enzymes Discovery Identifying commercially attractive & novel enzymes Engineering & formulation to enhance desired features Product Development & Manufacturing Cost efficient manufacturing Scalability & customisation Commercialisation B2B product offering => Early access Support for application development (integration into customer workflows) Biotec Pharmacon ASA 44

45 Pipeline Existing Product Portfolio s & Pipeline Concept Development Launch Growth Maturity rsap & Exo s Cod UNG s DNase s Polymerase s Proteinase s Key Elements Market Relevance: Focus on most commercial relevant enzymes Existing: Extracting maximum value from existing enzymes new uses in workflows & new formulations Pipeline: Regular introduction of new enzymes Synergistic Fit: Develop enzymes that can be combined together into customers kits and workflows Ligase s Biotec Pharmacon ASA 45

46 CAGR% ( ) Molecular Enzyme Market $1.5 Bil (2016) Existing Enzymes Cod UNG s, rsap, DNase s Polymerases 10 Ligases 8 6 Other Enzymes Reverse Transcriptases 4 2 Proteases & Proteinases Phosphatases Pipeline Enzymes Market Size ($Million) Adapted from Molecular Biology Enzymes and Kits & Reagents market Global Forecast to 2018; MarketsandMarkets Data excludes restriction enzymes. Biotec Pharmacon ASA 46

47 ArcticZymes Polymerases Represents the largest opportunity in the market for ArcticZymes Next Generation Sequencing Molecular Diagnostics Synthetic Biology Polymerase market is largest enzyme segment valued at $460 Mil (12% CAGR) 76% Thermostable Polymerases 24% Other Polymerase => Focus for ArcticZymes Polymerases represent the main engines driving the majority of workflows Overwhelming need in market for «Other polymerases» to serve «unmet» technical needs: Direct request from our commercial partners Recent acquisitions Companies have develop their own polymerases Status: By virtue of bioprospecting - enzyme properties nicely fit the underserved market Patenting is in process Provisional timeline - commercialise our first polymerase in 2016 or early 2017 Launch at least 2-3 different polymerase enzymes over the next 3 years Biotec Pharmacon ASA 47

48 Technical and Market Importance of Polymerases (compared to car industry) Technical Importance Market Importance Wing mirror motor (DNAases, Cod UNG, rsap) Accessory products; alternatives available. Thermostable polymerases resemble traditional fossil fuel engines Polymerases are engines that drive the majority of molecular workflows Engine (Polymerases) car cannot go without engine= polymerases are essential engines in workflows. AZ will serve market with several versions of Other Polymerases (No one enzyme fit all!) Other polymerases resemble electric engines for electric cars Biotec Pharmacon ASA 48

49 ArcticZymes Polymerases Represents the largest opportunity in the market for ArcticZymes Next Generation Sequencing Molecular Diagnostics Synthetic Biology Polymerase market is largest enzyme segment valued at $460 Mil (12% CAGR) 76% Thermostable Polymerases 24% Other Polymerase => Focus for ArcticZymes Polymerases represent the main engines driving the majority of workflows Overwhelming need in market for «Other polymerases» to serve «unmet» technical needs: Direct request from our commercial partners Recent acquisitions Companies have develop their own polymerases Status: By virtue of bioprospecting - enzyme properties nicely fit the underserved market Patenting is in process Provisional timeline - commercialise our first polymerase in 2016 or early 2017 Launch at least 2-3 different polymerase enzymes over the next 3 years Biotec Pharmacon ASA 49

50 B2B Product Sales ArcticZymes Approach to B2B Partnerships Supply Security Stages of customers commercial developments: Molecular Diagnostics (MDx): 2-4 years Molecular Research: 1-2 years Relevant to MDx only Scalable & Flexibility Win-Win Partnership (B2B) Quality (ISO 9001) Discovery & feasibility Development Testing & validation FDA/regulatory filing Launch & market penetration Engagement B2B Excellence: It s not just simply product it s a complete package offering Stages (B2B Sales Cycle) Biotec Pharmacon ASA 50

51 Short and Long-Term Priorities 2016 Focus on new product launches Embracing new relationships in MDx Global presence beyond USA 2018 Leverage value from synergic portfolio Recognised as a primary B2B supplier Revenues in excess of 50MNOK Biotec Pharmacon ASA 51

52 Outlook for ArcticZymes 50 MNOK Polymerases Proteinase s Ligases Others DNase s 20 MNOK rsap Cod UNG s More synergistic content and greater global presence Biotec Pharmacon ASA 52

53 Agenda Time Presentation Presenter Introduction Setting the scene CEO Svein Lien Innate immunity and Biotec s beta-glucans Woulgan product development Woulgan - wound care: Vision, positioning and market opportunity Market updates and commercial activities Product potential and outlook CSO Rolf Engstad VP Marketing Stuart Devine Immunotherapy of Cancer CSO Rolf Engstad Q&A All ArcticZymes value proposition MD Jethro Holter Q&A All Closing remarks and outlook CEO Svein Lien 2

54 Closing remarks and outlook Biotec Pharmacon ASA 5

55 OUTLOOK 2018 Full commercialization of Woulgan in key markets NOK100M in Group Revenues A cash positive and fully funded operation A strong product pipeline Enhance the value creation of ArcticZymes through organic growth, partnerships and strategic opportunities in the fast growing market for molecular enzymes Biotec Pharmacon ASA 55

56 OUTLOOK 2016 Enter into distribution agreement(s) for Woulgan in Germany Finalize the UK reimbursement process in the high-end category of the market Full launch in UK and Scandinavia Grow business further in Animal Health and Nutrition Achieve important milestones in the organic development of the ArcticZymes business and in the new enzyme development projects Biotec Pharmacon ASA 56